Affordable Access

Soft drug-resistant ovarian cancer cells migrate via two distinct mechanisms utilizing myosin II-based contractility

Authors
  • KAPOOR, A
  • BARAI, A
  • THAKUR, B
  • DAS, A
  • PATWARDHAN, SR
  • MONTEIRO, M
  • GAIKWAD, S
  • BUKHARI, AB
  • MOGHA, P
  • MAJUMDER, A
  • DE, A
  • RAY, P
  • SEN, S
Publication Date
Dec 03, 2018
Source
DSpace at IIT Bombay
Keywords
License
Unknown
External links

Abstract

The failure of chemotherapeutic drugs in treatment of various cancers is attributed to the acquisition of drug resistance. However, the migration mechanisms of drug-resistant cancer cells remain incompletely understood. Here we address this question from a biophysical perspective by mapping the phenotypic alterations in ovarian cancer cells (OCCs) resistant to cisplatin and paclitaxel. We show that cisplatin-resistant (CisR), paclitaxel-resistant (PacR) and dual drug-resistant (i.e., resistant to both drugs) OCCs are more contractile and softer than drug-sensitive cells. Protease inhibition suppresses invasion of CisR cells but not of PacR cells, indicative of a protease-dependent mode of migration in CisR cells and a protease-independent mode of migration in PacR. Despite these differences, actomyosin contractility, mediated by the RhoA-ROCK2-Myosin II signaling pathway, regulates both modes of migration. Confined migration experiments establish the role of myosin IIA and IIB in mediating nuclear translocation and regulation of proteolytic activity. Collectively, our results highlight the importance of myosin II as a potential therapeutic target for treatment of drug-resistant ovarian cancer cells.

Report this publication

Statistics

Seen <100 times